Anders Gülfe
Lund University
25 Papers
206 Citations
Anders Gülfe is an academic researcher from Lund University. The author has contributed to research in topics: Arthritis & Etanercept. The author has an hindex of 16, co-authored 25 publications. Previous affiliations of Anders Gülfe include Sahlgrenska University Hospital.
Chat about Author
Papers
•Journal Article
Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis
Lennart Jacobsson,Carl Turesson,Anders Gülfe,Meliha C Kapetanovic,Ingemar F Petersson,Tore Saxne,Pierre Geborek +6 more
TL;DR: It is suggested that the risk of developing CVD is lower in patients with RA treated with TNF blockers, compatible with the hypothesis that inflammation contributes to the development of cardiovascular events.
580
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
TL;DR: Concomitant MTX and high CRP levels are associated with treatment continuation of anti-TNF therapy in patients with PsA regardless of joint distribution, and the positive effect of MTX was primarily linked to fewer dropouts because of adverse events.
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register
J.A. Karlsson,Lars Erik Kristensen,Meliha C Kapetanovic,Anders Gülfe,Tore Saxne,Pierre Geborek +5 more
TL;DR: Responsibility rates of first-time anti-TNF switchers are somewhat below those of anti- TNF naïve RA patients, while the markedly inferior response rates of second-time Switchers suggest other therapeutic options to be considered in this situation.
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
Anders Gülfe,Lars Erik Kristensen,Tore Saxne,Lennart T H Jacobsson,Ingemar F Petersson,Pierre Geborek +5 more
TL;DR: There were weak or non-significant secular trends for increasing baseline utilities over time for RA, PsA and spondylarthritides over time, and EQ-5D proved feasible and applicable across these diagnoses.
Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents.
TL;DR: Disease activity states according to the various indices perform similarly and show substantial agreement at all levels except remission, and agreement between SDAI and CDAI states is excellent.